The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,590.00
Bid: 12,590.00
Ask: 12,596.00
Change: 74.00 (0.59%)
Spread: 6.00 (0.048%)
Open: 12,566.00
High: 12,632.00
Low: 12,512.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: FTSE Suffers Worst Fall Of 2014 As Fear Grips Market

Wed, 15th Oct 2014 16:33

LONDON (Alliance News) - UK stock indices closed significantly lower Wednesday, with the FTSE 100 suffering its worst one-day fall of the year so far. The sell-off was mirrored across Europe as markets were gripped by concern about a slowdown in growth amid disappointing economic data from around the world.

Volatility has returned to the markets in a big way, with the VIX volatility index reaching its highest level since since mid-2012, while global bond yields plunged to their lowest levels of the year and gold reached its highest level in more than a month as investors fled to the traditional safe havens.

The FTSE 100 ended the day down 2.8% at 6,211.64, shedding 181 points, which leaves the UK's leading index at its lowest level in 15 months. The mid-cap FTSE 250 ended the day down 1.7% at 14,426.74, and the small-cap AIM All-Share closed down 2.4% at 681.22, its lowest level in almost two years.

Major European equity markets also suffered heavy falls, with the French CAC 40 down a massive 3.6%, and the German DAX 30 down 2.9%. US stocks continued lower, with the DJIA, S&P 500 and Nasdaq Composite all down about 1.5% at the time of the European close. The DJIA slipped below 16,000 for the first time since February.

European indices started lower Wednesday amid ongoing concerns over the health of the eurozone economy, after early data from Germany showed consumer prices stagnated in September, for the second consecutive month. Those concerns were only compounded by continued declines in the price of oil, with Brent crude hitting a near four-year low in early trade, bottoming at USD83.35 per barrel.

Investors also remain concerned over the spread of Ebola, after a second healthcare worker in the US was confirmed to have caught the virus. The infected person was on an internal US flight on Monday night, and authorities are looking to contact the other passengers on the flight.

Global indices unwound further in afternoon trade after some disappointing US economic data showed retail sales there fell by 0.3% month-on-month in September, exceeding expectations for a 0.1% fall. The New York manufacturing index also contracted sharply in September, coming in at 6.17, down from 27.54 in August, while US producer price growth also turned negative, recording a month fall of 0.1%. The apparent slowing in US economic activity comes as a particular concern to investors given that it coincides with the end of the Federal Reserves quantitative easing programme later this month.

In London, Shire led the FTSE 100 lower from the outset Wednesday, plunging by a quarter at the open after US authorities appeared to get their way when AbbVie Inc said it is reconsidering its takeover of the Irish drug maker. The deal, which valued Shire at GBP32 billion, had been thrown into some doubt after US Treasury Secretary Jack Lew announced new measures last month to make so-called tax inversion deals less appealing. The news that AbbVie actually has gotten cold feed still took the markets by surprise, and Shire ended the day heavily lower at GBP39.43, not far from its mid-June price, when it originally rejected an advance from AbbVie.

Oil stocks were weighed down by oil prices, with Tullow Oil dropping 4.7%, Royal Dutch Shell falling 2.3%, Enquest down 5.7%, and Cairn Energy down 3.3%. BG Group held up relatively well against the sector decline, ending down just 0.5% after announcing that it poached Helge Lund from Norwegian rival Statoil to be its new chief executive from next March. Deutsche Bank sees the appointment as a positive step for BG, calling Lund an "industry heavyweight". Separately, BG Group said it had started production on the Iracema area in block BM-S-11 in the Santos Basin offshore Brazil early.

Royal Mail was the only FTSE 100 stock to record any significant gains, significantly outperforming the market and closing up 1.9% following the news Tuesday that it has sold one of its sites that is "recognised a surplus" for GBP111 million. Analysts at Berenberg say that the sale price was 85% above its own valuation, therefore indicating that Royal Mail shares may be significantly undervalued.

FTSE 250 listed CSR surged 30% after the semiconductor producer said it agreed to be acquired by US-based semiconductor company Qualcomm Inc for GBP1.6 billion in cash, a deal that comes after it has been in talks about a potential takeover with Microchip Technology Inc since August. The 900 pence a share bid from the US semiconductor group comes after CSR rebuffed an approach from Microchip Technology for being too low in August.

Balfour Beatty rose 11% on the news that it has poached the chief executive of defence products company QinetiQ Group to be its own CEO from January 1, 2015, a job that will involve turning the struggling company around after a string of profit warnings, a failed merger attempt from rival Carillion, and the disputed sale of its US project management business. Analysts have been positive over the appointment of new CEO Leo Quinn. Jefferies says he has a good track record as a turnaround specialist. QinetiQ was the worst performer in the FTSE 250, closing down 12%.

The most positive economic news of the day came from the UK Wednesday, where the unemployment rate fell to a six year low of 6.0% in August from 6.2% in July, exceeding expectations for a fall to 6.1%. Average earnings also improved a little faster that expected, rising by 0.9% in August, up from 0.8% in July and beating the expectation for the growth rate to remain unchanged.

A combination of the better UK data and weakness in the US dollar after the poor data across the pond sent the currency pair briefly back above USD1.60, although at the time of the equity market close the pound has weakened again to trade at USD1.5955.

Safe haven demand sent gold up to its highest level in more than a month, peaking at USD1,249.61 per ounce. The firmer price provided support for precious metal miner Fresnillo, which closed up 0.4% after raising its 2014 gold production target to 590,000 ounces.

There may be more volatility still to come Wednesday, with European Central Bank President Mario Draghi due to speak at 1900 BST from an International Monetary Fund event in Washington. The Federal Reserve's Beige Book of economic conditions is also due to be released at the same time.

Looking towards Thursday, eurozone consumer inflation data will be the morning focus, while from the US in the afternoon there is a raft of data including jobless claims and industrial production, as well as a number of speeches from Fed officials.

In the UK corporate calendar Thursday, drinks giant Diageo is due to make an interim management statement, as are Evraz, Mondi, and Man Group, among others. British Sky Broadcasting is due to release first-quarter results.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.